Key takeaways

  • Russian-developed nootropic peptide with regulatory approval as a prescription medicine in Russia for ischaemic stroke and cognitive indications.
  • Mechanism centres on BDNF / NGF modulation and neuroprotection — biologically plausible.
  • Russian RCT evidence in stroke recovery exists; Western independent replication is essentially absent.
  • Marketed widely as a "nootropic" — many of those claims are extrapolations beyond the trial population.
  • UK: unlicensed. Sold via research-chemical channels.

What it is

Semax is a synthetic 7-amino-acid peptide developed at Lomonosov Moscow State University in the 1980s. The first four residues (Met-Glu-His-Phe) correspond to ACTH(4-7); the additional Pro-Gly-Pro tail confers stability against proteolytic degradation while removing the corticotropic activity of native ACTH.

It received Russian regulatory approval in 1995 (initial registration) for ischaemic stroke recovery and was subsequently approved for additional cognitive indications. Approval in Russia is genuine and the trial evidence underlying that approval exists, primarily in Russian-language journals. Comparable approval has not been pursued outside the former Soviet sphere.

How it works

The proposed mechanism centres on BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) modulation. Animal data supports both the BDNF effect and downstream neuroprotection in ischaemia models.

Step 1
Intranasal administration

Most common route in clinical use; rapid CNS uptake.

Step 2
CNS penetration

Crosses the nasal mucosa; reaches CNS within minutes.

Step 3
BDNF / NGF modulation

Increases BDNF expression in animal models; downstream neurotrophic effects.

Step 4
Neuroprotection

Reduced infarct size in animal stroke models; foundational rationale.

Benefits

Stroke recovery (low–medium confidence in approved indication)

The Russian regulatory dataset includes RCTs in ischaemic stroke recovery that reported faster neurological recovery vs standard care. Effect sizes are modest. The Western literature lacks independent replication of similar magnitude.

Cognitive performance / focus (low confidence)

Russian research and small Western reports describe acute cognitive lift after intranasal Semax — improved attention and reduced subjective fatigue. The standardisation of cognitive batteries used is inconsistent across studies.

Replication outside the Russian context
Semax is meaningfully different from Epitalon in that it is a regulated prescription medicine in its country of origin — but the gap to Western evidence-based practice is still substantial. Independent replication in Western RCTs is sparse, and many marketed nootropic claims extend beyond the trial-validated indications.

Research summary

Semax in acute ischaemic stroke (Russian phase-3)
2002
Phase-3 RCT, Russian-language·n = 160

Improved neurological recovery and functional outcomes vs standard care in acute ischaemic stroke. Trial methodology consistent with the era; key reference for Russian regulatory approval.

Zh Nevrol Psikhiatr Im S S Korsakova · 102(5):17-21
Semax effects on BDNF expression in animal models
2008
Animal mechanism·n = Rats

Intranasal Semax increased BDNF expression in hippocampus and cortex following ischaemic injury. Provides mechanistic support for the neuroprotective hypothesis.

Brain Res Bull · 76(4):419-423
Cognitive effects of Semax in healthy volunteers
2014
Small RCT, Russian·n = 36

Intranasal Semax produced acute improvement in attention and working-memory tasks vs placebo. Small sample; not independently replicated.

Eksp Klin Farmakol · 77(10):3-5

Dosage & administration

No UK regulatory dosing. The schedule below summarises Russian SmPC ranges for the approved indications. Semax is unlicensed in the UK; this is educational reference only.

PhaseDoseDurationNotes
Stroke recovery (acute)600–1,800 µg/day5–14 daysRussian SmPC range
Cognitive use200–600 µg/dayVariableRussian protocol; Western data thin
Modern non-clinical use100–600 µg intranasalAcute, as-neededCommon research-channel pattern
Russian SmPC reference ranges. Not UK regulatory guidance.

Side effects & safety

Russian post-marketing data describes a benign side-effect profile at therapeutic doses. Western independent safety data is limited.

EffectFrequencySeverity
Nasal irritation5–10%Mild
Headache<5%Mild
Acute fatigue (paradoxical)AnecdotalTransient
Long-term effectsLimited Western dataUnknown

Contraindications: Pregnancy. Concurrent psychotropic medication (theoretical). Acute psychosis.

Unlicensed in the UK · POM in Russia
Semax has no marketing authorisation in the UK or EU. It is registered as a prescription medicine in the Russian Federation with approved indications including ischaemic stroke recovery. Sold in the UK via research-chemical channels only — quality and identity are not assured. Supply for human use without prescription is illegal under the Human Medicines Regulations 2012.

Summary

Semax is the most regulatory-credible "Russian peptide" we cover — a genuinely approved prescription medicine in its country of origin, with phase-3 RCT evidence in stroke recovery. The Western evidence is much thinner: limited independent replication, inconsistent cognitive-test methodologies, and a marketed nootropic positioning that extends beyond the trial-validated indications. UK readers should regard the stroke-recovery evidence as the most defensible — and treat extended cognitive claims with appropriate scepticism.

References (5)
  1. Skvortsova VI, et al. Semax in acute ischaemic stroke: phase-3 trial. Zh Nevrol Psikhiatr Im S S Korsakova. 2002;102(5):17-21.
  2. Romanova GA, et al. Semax effects on BDNF expression. Brain Res Bull. 2008;76(4):419-423.
  3. Levitskaya NG, Kamensky AA. Semax: 25 years of research. Neurochem J. 2009;3(1):8-21.
  4. Russian Federation State Register of Medicines. Semax 0.1% nasal drops. Registration certificate.
  5. MHRA. Note: Semax has no UK marketing authorisation as of May 2026.
This page has been peer-reviewed by a clinician. How we review content →